MARIE ROBIN (PARIS)
ALLO TRANSPLANTATION: WHEN AND HOW?
This presentation will first detail what are expected outcomes with and without transplantation in MDS
patients. The timing of transplantation will be analyzed according to disease and patients risk factors.
Generally, higher risk MDS patients benefit from upfront transplantation while lower risk do not.
Additional risk factors should be monitored in lower risk patients in order to decide or not to
transplant. Very high risk patients, especially those with poor genetic features have higher risk of post-transplant
relapse. In these cases, patients should be enrolled in trials tested strategies to limit relapse,
including post-transplant therapies.
SCIENTIFIC PROGRAMME
SESSION I
ETIOLOGY OF MDS
SESSION II
BIOLOGY OF MDS –
GENETIC ABNORMALITIES
SESSION III
BIOLOGY OF MDS:
STEM CELLS AND THE
MICROENVIRONMENT
SESSION IV
DIAGNOSTIC WORKUP
AND PROGNOSTIC
FACTORS IN MDS
SESSION V
SPECIFIC SUBTYPES
OF MDS, BASED ON
MORPHOLOGY AND
MOLECULAR BIOLOGY
SESSION VI
TREATMENT OF MDS
SESSION VII
CURRENT PROGRESS IN
THE TREATMENT OF MDS
SESSION VIII
FUTURE TREATMENTS
AND TREATMENT
STRATEGIES IN MDS
SESSION IX
LATE-BREAKING TALKS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES